Tags

Type your tag names separated by a space and hit enter

Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative.
Alzheimers Dement. 2015 Jul; 11(7):730-3.AD

Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI), designed as a naturalistic longitudinal study to develop and validate magnetic resonance, positron emission tomography, cerebrospinal fluid, and genetic biomarkers for use in AD clinical trials, has made many impacts in the decade since its inception. The initial 5-year study, ADNI-1, enrolled cognitively normal, mild cognitive impairment (MCI) and AD subjects, and the subsequent studies (ADNI-GO and ADNI-2) added early- and late-MCI cohorts. The development of standardized methods allowed comparison of data gathered across multiple sites, and these data are available to qualified researchers without embargo. ADNI data have been used in >600 publications including those describing relationships between biomarkers, improved methods for disease diagnosis and the prediction of future decline, and identifying novel genetic AD risk loci. ADNI has provided a framework for similar initiatives worldwide.

Links

PMC Free PDF

Authors+Show Affiliations

Weiner MW
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, CA, USA; Department of Psychiatry, University of California, San Francisco, CA, USA; Department of Neurology, University of California, San Francisco, CA, USA. Electronic address: michael.weiner@ucsf.edu.
Veitch DP
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA.

MeSH

Alzheimer DiseaseBrainComputer Communication NetworksDisease ProgressionHumansNeuroimagingPositron-Emission TomographyUnited States

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

26194308

Citation

Weiner, Michael W., and Dallas P. Veitch. "Introduction to Special Issue: Overview of Alzheimer's Disease Neuroimaging Initiative." Alzheimer's & Dementia : the Journal of the Alzheimer's Association, vol. 11, no. 7, 2015, pp. 730-3.
Weiner MW, Veitch DP. Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2015;11(7):730-3.
Weiner, M. W., & Veitch, D. P. (2015). Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia : the Journal of the Alzheimer's Association, 11(7), 730-3. https://doi.org/10.1016/j.jalz.2015.05.007
Weiner MW, Veitch DP. Introduction to Special Issue: Overview of Alzheimer's Disease Neuroimaging Initiative. Alzheimers Dement. 2015;11(7):730-3. PubMed PMID: 26194308.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Introduction to special issue: Overview of Alzheimer's Disease Neuroimaging Initiative. AU - Weiner,Michael W, AU - Veitch,Dallas P, PY - 2015/03/01/received PY - 2015/04/24/revised PY - 2015/05/05/accepted PY - 2015/7/22/entrez PY - 2015/7/22/pubmed PY - 2016/4/12/medline KW - Alzheimer's Disease Neuroimaging Initiative KW - Biomarkers KW - Governance KW - Standardization KW - Tau amyloid PET SP - 730 EP - 3 JF - Alzheimer's & dementia : the journal of the Alzheimer's Association JO - Alzheimers Dement VL - 11 IS - 7 N2 - The Alzheimer's Disease Neuroimaging Initiative (ADNI), designed as a naturalistic longitudinal study to develop and validate magnetic resonance, positron emission tomography, cerebrospinal fluid, and genetic biomarkers for use in AD clinical trials, has made many impacts in the decade since its inception. The initial 5-year study, ADNI-1, enrolled cognitively normal, mild cognitive impairment (MCI) and AD subjects, and the subsequent studies (ADNI-GO and ADNI-2) added early- and late-MCI cohorts. The development of standardized methods allowed comparison of data gathered across multiple sites, and these data are available to qualified researchers without embargo. ADNI data have been used in >600 publications including those describing relationships between biomarkers, improved methods for disease diagnosis and the prediction of future decline, and identifying novel genetic AD risk loci. ADNI has provided a framework for similar initiatives worldwide. SN - 1552-5279 UR - https://www.unboundmedicine.com/medline/citation/26194308/Introduction_to_special_issue:_Overview_of_Alzheimer's_Disease_Neuroimaging_Initiative_ DB - PRIME DP - Unbound Medicine ER -